Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Warrant (NQ: TVGNW )

0.0682 +0.0027 (+4.12%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 124,123
Open 0.0699
Bid (Size) 0.0600 (9)
Ask (Size) 0.1000 (2)
Prev. Close 0.0655
Today's Range 0.0571 - 0.0750
52wk Range 0.0099 - 0.1499
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire

Performance

YTD
+13.67%
+13.67%
1 Month
-24.14%
-24.14%
3 Month
+33.46%
+33.46%
6 Month
+175.00%
+175.00%
1 Year
+36.40%
+36.40%

More News

Read More
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
From Tevogen Bio Inc
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
From Tevogen Bio Inc
Via GlobeNewswire
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
From Tevogen Bio Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.